ArticleCellular oncology (Dordrecht, Netherlands)2026
Lactylation shields S100A11 from degradation to promote gastric cancer metastasis.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProtein lactylation, a novel post-translational modification utilizing lactate as the substrate, has emerged as a key mechanism linking metabolic alterations to cancer progression. This study aims to investigate the role and underlying mechanism of S100A11 lactylation in gastric cancer progression and metastasis.
methodsLactylome profiling, site-directed mutagenesis, co-IP, cycloheximide chase, ubiquitination assays, and in vitro/in vivo functional experiments were performed to dissect the regulatory effect of S100A11 lactylation.
resultsS100A11 was identified as a hyperlactylated protein in gastric cancer tissues, with lysine 27 (K27) and lysine 55 (K55) serving as the primary modification sites. Mechanistically, lactylation at K27 and K55 disrupted the interaction between S100A11 and its E3 ubiquitin ligase FBXW11, thereby inhibiting polyubiquitination and proteasomal degradation of the protein. The K27R/K55R double mutation, which abolished both lactylation and ubiquitination at these residues, resulted in constitutive stabilization of S100A11. The stabilized S100A11 hyperactivated the PI3K-AKT and ERK1/2 signaling cascades and upregulated the downstream oncogenic effectors Cyclin D1 and c-Myc. Functionally, S100A11 stabilization significantly enhanced the proliferation, colony formation, migration and invasion of gastric cancer cells in vitro, and markedly promoted lung metastasis in vivo. Clinically, higher lactylation levels of S100A11 were observed in patients with advanced TNM stages.
conclusionThis study reveals a lactylation-ubiquitination competitive regulatory mechanism that governs S100A11 protein stability, which directly links Warburg effect-derived lactate to oncogenic protein stabilization and metastatic progression in gastric cancer.
Indexed as
Identifiers
42423863What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.